Handelsbanken Fonder AB increased its holdings in shares of Danaher Corporation (NYSE:DHR – Free Report) by 25.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 279,879 shares of the conglomerate’s stock after purchasing an additional 57,013 shares during the period. Handelsbanken Fonder AB’s holdings in Danaher were worth $64,070,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Elevated Capital Advisors LLC bought a new position in Danaher during the fourth quarter worth about $26,000. JPL Wealth Management LLC bought a new position in Danaher during the third quarter worth about $25,000. WFA of San Diego LLC bought a new position in Danaher during the second quarter worth about $26,000. ANTIPODES PARTNERS Ltd bought a new position in Danaher during the third quarter worth about $27,000. Finally, Financial Life Planners bought a new position in Danaher during the third quarter worth about $32,000. Institutional investors own 79.05% of the company’s stock.
Danaher Stock Performance
Shares of NYSE:DHR opened at $164.08 on Tuesday. The business’s fifty day moving average price is $185.54 and its two-hundred day moving average price is $209.93. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The stock has a market capitalization of $116.13 billion, a price-to-earnings ratio of 31.74, a price-to-earnings-growth ratio of 2.16 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.87 and a quick ratio of 1.52.
Danaher Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Friday, June 26th. Danaher’s dividend payout ratio is 30.95%.
Wall Street Analyst Weigh In
DHR has been the subject of a number of research analyst reports. Rothschild & Co Redburn set a $205.00 price target on Danaher in a report on Friday, April 17th. JPMorgan Chase & Co. cut their price objective on shares of Danaher from $275.00 to $245.00 and set an “overweight” rating for the company in a research report on Wednesday, April 22nd. Wall Street Zen downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Jefferies Financial Group restated a “buy” rating and set a $245.00 price objective on shares of Danaher in a research report on Tuesday, April 21st. Finally, UBS Group cut their price objective on shares of Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Nineteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $238.65.
Read Our Latest Analysis on Danaher
Insider Buying and Selling
In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total value of $274,573.20. Following the transaction, the executive vice president owned 5,099 shares of the company’s stock, valued at approximately $1,060,642.99. The trade was a 20.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.80% of the company’s stock.
Danaher Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Featured Stories
- Five stocks we like better than Danaher
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
